^
    1year
    Towards a New Horizon in Prostate Cancer: PSMA-Targeted Docetaxel-Conjugated Nanomedicines for Intratumoral Treatment in Xenograft Model (AUA 2023)
    Docetaxel-conjugated mesoporous silica nanomedicines effectively reduced tumor volume in intratumoral administration using a nude mice PC xenograft model. These results are promising, paving the way for a future applicability as a precision intratumoral medicine for PC in humans.
    Preclinical
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 overexpression
    |
    PSMA-targeted docetaxel (BIND-014)